
CymaBay Therapeutics Investor Relations Material
Latest events

Q3 2023
CymaBay Therapeutics

Q4 2023
22 Feb, 2024

Corporate Presentation
21 Dec, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CymaBay Therapeutics Inc
Access all reports
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. It is developing seladelpar, which is in Phase IIb clinical trials for the treatment of primary biliary cholangitis (PBC) and in Phase II trials for the treatment of bile acid diarrhea; MBX-2982 that is in preclinical development stage; and MBX-8025 to treat homozygous familial hypercholesterolemia. The company was founded in 1989 and is headquartered in Newark, California.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CBAY
Country
🇺🇸 United States